

# AI for Rare Disease Diagnosis: Shortening the Diagnostic Odyssey

Rasit Dinc

*Rasit Dinc Digital Health & AI Research*

Published: October 7, 2024 | Medical Imaging AI

DOI: [10.5281/zenodo.17996952](https://doi.org/10.5281/zenodo.17996952)

## Abstract

The journey to a rare disease diagnosis is often described as a "diagnostic odyssey," a prolonged and emotionally taxing period that can span years or even decades. With over 7,000 identified rare diseases, affecting an estimated 300 million people globally, the challenge lies in their low prevalence and the heterogeneity of their symptoms, which often mimic more common conditions [1]. However, the convergence of artificial intelligence (AI) and digital health is now offering a powerful solution, transforming this arduous journey into a path of precision and speed.

## The Challenge of Rarity and Complexity

Rare diseases, defined in the US as conditions affecting fewer than 200,000 people, present a unique set of diagnostic hurdles. Clinicians may encounter a specific rare disease only once or twice in their entire career, leading to misdiagnosis or significant delays. The average time to diagnosis is estimated to be between four and seven years, a critical window during which irreversible disease progression can occur [2]. The complexity is compounded by the reliance on specialized genetic testing and the need to synthesize vast amounts of clinical data, including patient history, imaging, and biochemical results.

## AI's Role in Decoding the Undecipherable

Artificial intelligence, particularly machine learning (ML) and deep learning (DL), excels at pattern recognition in high-dimensional data—a perfect fit for the diagnostic challenges of rare diseases. AI systems are being trained on massive datasets of genomic information, electronic health records (EHRs), and medical images to identify subtle, often overlooked, disease signatures.

### ***Success Story 1: Genomic Analysis and Variant Prioritization***

One of the most significant successes of AI is in the interpretation of whole-

exome and whole-genome sequencing data. For patients with suspected genetic disorders, sequencing can yield thousands of genetic variants, only one or a few of which may be pathogenic. AI algorithms can rapidly prioritize these variants by integrating knowledge from public databases, predicted functional impact, and the patient's clinical phenotype (symptoms) [3].

For example, systems using **Natural Language Processing (NLP)** to analyze clinical notes and match phenotypic descriptions (using standardized terms like the Human Phenotype Ontology) with known disease-gene associations have dramatically reduced the time required for variant filtering. This process, which previously took geneticists weeks, can now be completed in hours, leading to faster diagnoses for conditions like Gaucher disease and various congenital muscular dystrophies [4].

### ***Success Story 2: Image-Based Phenotyping***

AI is also revolutionizing the use of medical imaging and facial analysis. Many rare genetic syndromes manifest with distinct facial features (dysmorphism). Deep learning models, such as those used in the Face2Gene platform, are trained on large collections of patient photographs to identify these subtle patterns. By analyzing a patient's photograph, the AI can generate a list of potential syndromes, effectively guiding the clinician toward the correct genetic test [5]. This non-invasive, rapid screening tool has proven particularly valuable in pediatric rare disease diagnosis, where early intervention is paramount.

Similarly, AI is being applied to retinal scans, MRIs, and X-rays to detect subtle structural abnormalities indicative of rare diseases. For instance, DL models can identify the characteristic "beading" of the ribs in mucopolysaccharidosis or the specific white matter lesions in leukodystrophies, often before a human eye might recognize the pattern [6].

### **The Future: Integrated Digital Health and AI**

The future of rare disease diagnosis lies in the seamless integration of these AI tools into the clinical workflow. This includes AI-powered clinical decision support systems that alert general practitioners to the possibility of a rare disease based on a combination of seemingly unrelated symptoms in a patient's EHR.

While the technology is rapidly advancing, the ethical and regulatory frameworks must evolve in parallel to ensure equitable access and responsible deployment. The collaboration between clinicians, data scientists, and patient advocacy groups is essential to build and validate robust, unbiased AI models.

For more in-depth analysis on the ethical considerations, data governance, and the future trajectory of digital health and AI in medicine, the resources at [www.rasitdinc.com](<https://www.rasitdinc.com>) provide expert commentary and professional insight.

### **Conclusion**

AI is not merely an incremental improvement; it is a fundamental shift in how

we approach the most challenging diagnostic cases in medicine. By leveraging the power of machine learning in genomics, imaging, and clinical data analysis, AI is successfully shortening the diagnostic odyssey for millions of patients with rare diseases, ushering in an era of earlier intervention and improved quality of life. The success stories emerging today are a testament to the transformative potential of this technology in digital health.

\*\*

### **References**

[1] Schaefer, J., et al. (2020). *The use of machine learning in rare diseases: a scoping review*. *Orphanet Journal of Rare Diseases*, 15(1), 185. [<https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01424-6>] [2] Visibelli, A., et al. (2023). *The Impact of Artificial Intelligence in the Odyssey of Rare Diseases*. *International Journal of Molecular Sciences*, 24(7), 6335. [<https://pmc.ncbi.nlm.nih.gov/articles/PMC10045927/>] [3] Wojtara, M., et al. (2023). *Artificial intelligence in rare disease diagnosis and treatment*. *Molecular Genetics & Genomic Medicine*, 11(11), e2276. [<https://pmc.ncbi.nlm.nih.gov/articles/PMC10651639/>] [4] Frías, M., et al. (2025). *The artificial intelligence challenge in rare disease diagnosis*. *Clinical Genetics*, 107(3), 255-263. [<https://www.sciencedirect.com/science/article/pii/S0010482525009618>] [5] UCSF News. (2024). *Using AI to Improve Detection of Rare Diseases*. [<https://www.ucsf.edu/news/2024/07/428071/using-ai-improve-detection-rare-diseases>] [6] Nishat, S. M. H., et al. (2025). *A New Frontier in Rare Disease Early Diagnosis*. *Cureus\**, 17(2). [<https://www.cureus.com/articles/341528-artificial-intelligence-a-new-frontier-in-rare-disease-early-diagnosis>]

---